James Kihara - Sep 15, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Sep 15, 2023
Transactions value $
-$51,760
Form type
4
Date filed
9/19/2023, 06:31 PM
Previous filing
Jun 16, 2023
Next filing
Nov 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Sale -$51.8K -2K -15.65% $25.88 10.8K Sep 15, 2023 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
F2 Includes an aggregate of 3,611 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on November 13, 2020, May 14, 2021, November 15, 2021, May 13, 2022, November 15, 2022 and May 15, 2023.
F3 Includes 23 shares purchased by the Reporting Person in open market transaction on November 21, 2020, with a purchase price of $43.01 per share.